About Succipro
Our story
Succipro was founded in 2022 as a spin-off of IRB CatSud (formerly known as the Pere i Virgili Health Research Institute, IISPV) and the Rovira i Virgili University (URV), driven by the desire to turn scientific discoveries into real therapeutic solutions. With a solid foundation in research on succinate as a therapeutic target, we have evolved to become a benchmark in the development of succinate-modulating drugs targeting metabolic and inflammatory diseases.
Our journey is marked by collaboration with scientific institutions, pharmaceutical companies, and investors, which allows us to advance toward safe and effective solutions that transform the lives of patients.
Our team
We have a multidisciplinary team made up of researchers, scientists, physicians, and highly qualified professionals with an extensive track record in drug development and the treatment of chronic diseases.
Additionally, we work closely with internationally renowned specialists and collaborate with leading academic institutions to ensure that our projects remain at the forefront of scientific and pharmaceutical innovation.
Executive Team
Isabel Huber PhD, MBA
CEO, Co-founder, and Board Member
Pharmacist with a PhD in Biochemistry from the University of Barcelona and an MBA in Biotechnology from Barcelona, with more than 10 years of experience in preclinical research.
Sonia Fernández-Veledo, PhD
Scientific Director, Co-founder, and Board Member
Biochemist and PhD in Biomedicine, key opinion leader in succinate biology with more than 100 publications and an H-index of 44 (according to Google Scholar), principal investigator of the DIAMET group.
Joan Vendrell, MD, PhD
Chief Medical Officer, Co-founder, and Board Member
Attending Physician at the Joan XXIII University Hospital and Professor at the Rovira i Virgili University, author of more than 150 scientific publications and an H-index of 79 (according to Google Scholar). Clinical Coordinator of the DIAMET research group.
Vicenç Tur, MBA
Chief Financial Officer and Board Member
Bachelor’s degree in Business Administration (UIB) and Economics (UAB), as well as an MBA. He has extensive experience in managing R&D projects in innovative companies, with more than 25 years of experience as a (co)founder, CEO, CFO, and CBO.
Carolina Salcedo, PhD
Development Director
Biologist with a PhD in Pharmacology and more than 35 years of experience in drug development. Author of 15 patents and 21 publications, and a participant in more than 20 development programs with 4 marketed drugs. CSO of Sanifit for 13 years, taking SNF472 from preclinical to Phase 3.
Esteban Plata, PhD, MBA
Board Member
PhD in Biotechnology and MBA. Pharmaceutical industry executive with more than 32 years of experience. Esteban has been President and Corporate Officer of AbbVie for Europe and Canada, based in Paris, as well as President of Japan, Asia, and Australia, based in Singapore, and General Manager in several countries, including Spain, Japan, and Turkey.
R&D Team
Marjorie Reyes, PhD
Senior Researcher. Preclinical Drug Research
Biochemist with a PhD in Food and Nutrition and 10 years of experience in scientific research with a translational focus. Her career includes studies on inflammation, drug development, and metabolic and intestinal diseases.
Joan A. Soler, PhD
Senior Researcher. Drug development and characterization
Chemist with a PhD in Biosciences and more than 8 years of international research experience at the Max Planck Institute. Specialized in biochemistry, cell biology, and the characterization of biomolecules using analytical techniques and biophysical methods.
Joan Miquel Màrmol, MSc
Junior Preclinical Researcher
Molecular biologist with 5 years of international research experience at the University of Copenhagen, specializing in in vivo procedures oriented toward drug development. Experience focused on the implementation and optimization of experimental models for preclinical evaluation.
External Advisors
Manuel Barreiro, MD, PhD
Gastroenterologist
Head of the Inflammatory Bowel Disease (IBD) Unit at the University Clinical Hospital of Santiago de Compostela, Spain. He served as president of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) from 2019 to 2021. He is also a member of the European Crohn’s and Colitis Organisation (ECCO) and the ECCO Education Committee (EDUCOM).
José Manuel Fernández-Real, MD, PhD
Endocrinologist
Endocrinologist and researcher at the Dr. Josep Trueta Biomedical Research Institute of Girona. He has more than 25 years of experience in the study of obesity, insulin resistance, and associated metabolic disorders.
Jesús Seco, PhD
Consultant in Computational Drug Design
Bachelor’s degree in Chemistry with a PhD in Computational Biology. He has more than 15 years of experience in computational chemistry and bioinformatics, working with advanced AI and state-of-the-art (SOTA) methodologies to build robust predictive models for drug design.
Cesyen Cedeño, PhD
CMC Consultant (Biologics Manufacturing Process)
Chemist with a PhD in Bioengineering. Specialist in pharmaceutical product manufacturing processes under Good Manufacturing Practices (GMP) standards, regulatory advisory, and quality management.
Gloria Martín, MSc
Regulatory Affairs Consultant
Bachelor’s degree in Chemistry. More than 35 years of experience in the pharmaceutical and biotechnology industry in the field of regulatory affairs management and coordination, including more than 23 years at Ferrer Internacional.